Salivary **cathelicidin LL-37** levels rise progressively, detecting **oral squamous cell carcinoma** with high sensitivity.
Background
Oral squamous cell carcinoma (OSCC) is the most common oral malignancy, often diagnosed late, leading to poor prognosis. Oral potentially malignant disorders (OPMDs) frequently precede OSCC, highlighting a critical need for early, non-invasive diagnostic biomarkers. Current diagnostic methods often involve invasive biopsies, which can delay diagnosis and treatment. Identifying reliable biomarkers like cathelicidin LL-37, an antimicrobial peptide involved in innate immunity and inflammation, could enable earlier intervention and improve patient outcomes by detecting oral carcinogenesis at its nascent stages.
Study Design
Researchers quantified salivary cathelicidin LL-37 levels using ELISA in 80 participants. The study population was divided into four distinct groups: healthy controls, individuals with tobacco-associated OPMDs, those with non-tobacco-associated OPMDs, and patients diagnosed with OSCC. This design allowed for a progressive comparison of biomarker levels across different stages of oral carcinogenesis. Saliva samples were collected non-invasively, and the primary endpoint was the diagnostic accuracy of LL-37 levels for distinguishing between these groups.
Results
Salivary cathelicidin LL-37 levels demonstrated a significant and progressive increase across the study groups, rising from healthy controls through OPMDs to OSCC cases (p < 0.001). This dose-response-like trend suggests a strong correlation between elevated LL-37 and the progression of oral carcinogenesis. The progressive increase in LL-37 levels provides a clear gradient, making it a strong candidate for a diagnostic marker across different stages of disease.
For detecting OSCC, salivary LL-37 achieved remarkable diagnostic performance, exhibiting 100% sensitivity and 90% specificity. This indicates that LL-37 is highly effective at identifying true positive cases of oral cancer while maintaining a low false-positive rate. The robust statistical significance (p < 0.001) underscores the reliability of these findings, positioning LL-37 as a promising candidate for a non-invasive diagnostic tool.
Why It Matters
This research offers a significant step towards a non-invasive, early detection method for oral squamous cell carcinoma (OSCC), potentially transforming current diagnostic protocols. Salivary LL-37 could enable routine screening for high-risk individuals and monitoring of OPMDs, reducing reliance on invasive biopsies and facilitating earlier treatment. For clinicians, this means a simpler, patient-friendly tool to identify oral carcinogenesis at a stage where interventions are most effective. While this study provides compelling evidence, further validation in larger, diverse cohorts is needed before clinical implementation. However, the high sensitivity and specificity suggest a strong potential for LL-37 to become a standard biomarker, improving prognosis by catching cancer earlier.
